- Current report filing (8-K)
19 Dicembre 2012 - 12:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 18, 2012
KIWA BIO-TECH PRODUCTS GROUP CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
000-33167
|
|
77-0632186
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
|
310 N. Indian Hill Blvd., #702
Claremont, California
|
|
|
|
|
(Address of principal
executive offices)
|
|
|
|
|
|
|
|
|
|
91711
|
|
|
|
|
(Zip code)
|
|
|
|
|
|
|
|
|
|
(626) 715-5855
|
|
|
|
|
(Registrant’s telephone
number, including area code)
|
|
|
|
|
|
|
|
|
|
None.
|
|
|
|
|
(Former name or
former
address, if changed since last report)
|
|
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07. Submission of Matters to
a Vote of Security Holders
On December 18, 2012, Kiwa Bio-Tech Products
Group Corporation, a Delaware corporation (the “Company”), held an annual meeting of its stockholders (the “Annual
Meeting”). Present at the Annual Meeting, in person or by proxy, were holders of 268,354,283 shares of the Company’s
common stock, or 67.1% of all shares eligible to vote on the subject proposals.
Proposal 1
Messrs. Wei Li, Lianjun Luo, Xucheng Hu, and
Prof. Qi Wang were elected to the Company’s board of directors for the term of one year as follows:
|
|
For
|
|
Against
|
|
Withhold
|
|
Broker Non-Votes
|
Nominees:
|
|
|
|
|
|
|
|
|
(1) Wei Li
|
|
98,542,398
|
|
-
|
|
976,041
|
|
284,160,363
|
(2) Xucheng Hu
|
|
98,925,398
|
|
-
|
|
584,041
|
|
284,169,363
|
(3) Lianjun Luo
|
|
98,925,398
|
|
-
|
|
584,041
|
|
284,169,363
|
(4) Qi Wang
|
|
98,925,398
|
|
-
|
|
584,041
|
|
284,169,363
|
Proposal 2
Paritz & Company, P.A. was ratified as
the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012. The voting totals
were as follows:
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
Paritz & Company, P. A.
|
|
265,587,680
|
|
217,161
|
|
2,549,442
|
|
115,324,519
|
Proposal 3
The proposal to amend our Certificate of Incorporation
to increase the total number of authorized shares from 400,000,000 to 800,000,000 shares was not approved. The voting totals were
as follows:
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
Increase authorized shares
|
|
115,060,067
|
|
150,838,371
|
|
2,455,842
|
|
115,324,522
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 18, 2012
KIWA BIO-TECH PRODUCTS GROUP CORPORATION
By:
|
/s/ Wei Li
|
|
|
Wei Li
|
|
|
Chief Executive Officer and Chairman of Board of Directors
|
Grafico Azioni Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Storico
Da Giu 2023 a Giu 2024